Preclinical and clinical data indicate distinct therapeutic vulnerabilities across SCLC subtypes: SCLC-A exhibits variable sensitivity to platinum-based agents, alongside potential responses to BCL2 inhibitors and DLL3-targeted therapies. The gene discussed is DLL3; the disease is small cell lung carcinoma.